

# Tilman B Drueke

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2730338/publications.pdf>

Version: 2024-02-01

14  
papers

44  
citations

2258059

3  
h-index

1872680

6  
g-index

15  
all docs

15  
docs citations

15  
times ranked

55  
citing authors

#	ARTICLE	IF	CITATIONS
1	Stiripentol for the treatment of primary hyperoxaluria and calcium oxalate nephropathy. <i>Kidney International</i> , 2020, 97, 17-19.	5.2	17
2	Role of proteinuria in the anemia of chronic kidney disease. <i>Kidney International</i> , 2021, 100, 1160-1162.	5.2	5
3	Diet–microbiota interaction and kidney disease progression. <i>Kidney International</i> , 2021, 99, 797-800.	5.2	4
4	Running interference: lumasiran and other RNA interference therapeutics for kidney diseases. <i>Kidney International</i> , 2022, 101, 208-211.	5.2	3
5	Bone biopsy in chronic kidney disease: still an option?. <i>Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia</i> , 2020, 42, 130-132.	0.9	3
6	Vitamin D deficiency and chronic kidney disease risk: cause or merely association?. <i>American Journal of Clinical Nutrition</i> , 2018, 108, 1164-1165.	4.7	2
7	Kidney toxicity of phosphate: is that crystal clear yet?. <i>Kidney International</i> , 2021, 100, 1155-1157.	5.2	2
8	Role of FGF23 in clinical outcomes of patients with chronic kidney disease. <i>Kidney International</i> , 2021, 100, 993-994.	5.2	2
9	Role of uremic toxins in vascular disease—the end of nihilism?. <i>Kidney International</i> , 2022, 101, 1100-1102.	5.2	2
10	A new player in the kidney–bone axis: regulation of fibroblast growth factor-23 by renal glycerol-3-phosphate. <i>Kidney International</i> , 2020, 98, 1074-1076.	5.2	1
11	Low turnover bone disease in early CKD stages. <i>Kidney International Reports</i> , 2022, , .	0.8	1
12	The Authors Reply. <i>Kidney International Reports</i> , 2020, 5, 2403-2404.	0.8	0
13	Increase in phosphaturia by inhibition of renal sodium-dependent phosphate cotransporter NPT2a. <i>Kidney International</i> , 2021, 99, 533-536.	5.2	0
14	Cardiovascular and renal risk reduction in type 2 diabetes—which choice?. <i>Kidney International</i> , 2021, 99, 322-323.	5.2	0